Indication name: Alpha-1
antitrypsin deficiency
Alpha-1
antitrypsin deficiency (AATD) – Market outlook, Epidemiology, Market Forecast
and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany,
France, Spain, United Kingdom, Italy, Japan & China)
Alpha-1 antitrypsin
deficiency (Alpha-1 or AATD) is an autosomal codominant genetic condition that
can result in serious lung disease in adults and/or liver disease at any age.
AATD occurs when the blood is deficient in a protein called Alpha-1
antitrypsin, or AAT. AAT is mainly produced by the liver, and its primary
function is to protect the lungs from increased protease activity. The
responsible gene, SERPINA1, is located on the long arm of chromosome 14
(14q31–32.3)
Epidemiology-
According to Thelansis disease modeling data and literature review estimated
~78000 patients with AATD in the United States in the year 2020.
Competitive
landscape of Alpha-1 antitrypsin deficiency includes country specific approved
as well as pipeline therapies. Any asset/ product specific designation or
review and Accelerated Approval are being tracked and supplemented with analyst
commentary.
KOLs
insights of Alpha-1 antitrypsin deficiency 8 MM market from center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm and Unmet needs.
Alpha-1 antitrypsin deficiency market forecast: Patient Based Forecast Model
(MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market
Event and Product Event, Country specific Forecast Model, Market uptake and patient
share uptake, Attribute Analysis, Analog Analysis, Disease
burden and pricing scenario, Summary and Insights.
S. No Asset Company
Stage
1 Aerosolized, Recombinant Alpha 1-Antitrypsin Arriva Pharmaceuticals, Inc.
Phase 2
2 Alpha-1 15% Grifols Therapeutics LLC Phase 2
3 ADVM-043 Adverum Biotechnologies, Inc. Phase 2
4 Alpha 1-Antitrypsin Kamada, Ltd. Phase 3
5 INBRX-101/rhAAT-Fc Inhibrx, Inc. Phase 1
6 ARO-AAT Injection Arrowhead Pharmaceuticals Phase 2
7 belcesiran Dicerna Pharmaceuticals, Inc. Phase 2
8 rAAV1-CB-hAAT Applied Genetic Technologies Corp Phase 2
9 VX-864 Vertex Pharmaceuticals Incorporated Phase 2
10 ZF874 Z Factor Limited Phase 1
11 Carbamazepine (Tegretol XR) Novartis Phase 22
No comments:
Post a Comment